Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-12-12

Clinical Trial Update: Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for axitinib in unresectable hepatocellular carcinoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Axitinib (Axitinib)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED